MX2017014567A - Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos. - Google Patents

Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos.

Info

Publication number
MX2017014567A
MX2017014567A MX2017014567A MX2017014567A MX2017014567A MX 2017014567 A MX2017014567 A MX 2017014567A MX 2017014567 A MX2017014567 A MX 2017014567A MX 2017014567 A MX2017014567 A MX 2017014567A MX 2017014567 A MX2017014567 A MX 2017014567A
Authority
MX
Mexico
Prior art keywords
cytokine
mediated diseases
protein
disorders
methods
Prior art date
Application number
MX2017014567A
Other languages
English (en)
Inventor
Mercurio Frank
Fung Leah
E Erdman Paul
Sullivan Robert
W H Chan Kyle
Original Assignee
Biotheryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheryx Inc filed Critical Biotheryx Inc
Publication of MX2017014567A publication Critical patent/MX2017014567A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención proporciona moduladores de la función de las proteínas, para restaurar la homeostasis de proteínas, incluyendo citocina, actividad de aiolos, y/o ikaros, y la adhesión célula-célula. La invención proporciona métodos para modular enfermedades mediadas por proteínas, tal como enfermedades, trastornos, condiciones, o respuestas mediadas por citocinas. Se proporcionan composiciones, incluyendo en combinación con otros mediadores inflamatorios y citocinas. Se proporcionan métodos de tratamiento, mejora, o prevención de enfermedades, trastornos, y condiciones mediadas por proteínas, tal como enfermedades, trastornos, y condiciones mediadas por citocinas, incluyendo inflamación, fibromialgia, artritis reumatoide, osteoartritis, espondilitis anquilosante, psoriasis, artritis psoriática, enfermedad de intestino inflamatorio, enfermedad de Crohn, colitis ulcerativa, uveítis, enfermedades pulmonares inflamatorias, enfermedad pulmonar obstructiva crónica, enfermedad de Alzheimer, y cáncer.
MX2017014567A 2015-05-22 2016-05-18 Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos. MX2017014567A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562165469P 2015-05-22 2015-05-22
PCT/US2016/033133 WO2016191178A1 (en) 2015-05-22 2016-05-18 Compounds targeting proteins, compositions, methods, and uses thereof

Publications (1)

Publication Number Publication Date
MX2017014567A true MX2017014567A (es) 2018-06-28

Family

ID=56194555

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017014567A MX2017014567A (es) 2015-05-22 2016-05-18 Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos.

Country Status (16)

Country Link
US (2) US9822098B2 (es)
EP (1) EP3298004B1 (es)
JP (2) JP6629885B2 (es)
KR (1) KR102055491B1 (es)
CN (1) CN107787320B (es)
AU (1) AU2016266942B2 (es)
CA (1) CA2986141C (es)
HK (1) HK1253065A1 (es)
IL (1) IL255589B (es)
MX (1) MX2017014567A (es)
NZ (1) NZ737355A (es)
RU (1) RU2694895C2 (es)
SG (1) SG11201708303XA (es)
TW (1) TWI650320B (es)
WO (1) WO2016191178A1 (es)
ZA (1) ZA201707749B (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017014567A (es) 2015-05-22 2018-06-28 Biotheryx Inc Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos.
CN109475528B (zh) 2016-04-22 2022-01-11 达纳-法伯癌症研究所股份有限公司 用于egfr降解的双功能分子和使用方法
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
EP3455218A4 (en) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION
CN109562113A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的螺环降解决定子体
WO2017201069A1 (en) * 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators
MX2019007434A (es) * 2016-12-21 2019-08-16 Biotheryx Inc Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos.
WO2018169777A1 (en) * 2017-03-14 2018-09-20 Biotheryx, Inc. Compounds targeting proteins, compositions, methods, and uses thereof
EP3641762A4 (en) 2017-06-20 2021-03-10 C4 Therapeutics, Inc. N / O BONDED DEGRONS AND DEGRONIMERS FOR PROTEIN DEGRADATION
TWI793151B (zh) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-氧異吲哚啉-2-基)之氫吡啶-2,6-二酮衍生物及其用途
US10513515B2 (en) * 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN111278816B (zh) 2017-09-04 2024-03-15 C4医药公司 二氢喹啉酮
WO2019043217A1 (en) 2017-09-04 2019-03-07 F. Hoffmann-La Roche Ag DIHYDROBENZIMIDAZOLONES
EP3679026A1 (en) 2017-09-04 2020-07-15 C4 Therapeutics, Inc. Glutarimide
EP3710002A4 (en) 2017-11-16 2021-07-07 C4 Therapeutics, Inc. DEGRADER AND DEGRONE FOR TARGETED PROTEIN DEGRADATION
US11773080B2 (en) 2017-12-22 2023-10-03 Salarius Pharmaceuticals, Inc. Deuterium-enriched isoindolinonyl-azepanediones and related compounds and methods of treating medical disorders using same
WO2019173224A1 (en) * 2018-03-05 2019-09-12 Biotheryx, Inc. Deuterated compounds and chimeras and uses thereof
CN111902141A (zh) 2018-03-26 2020-11-06 C4医药公司 用于ikaros降解的羟脑苷脂结合剂
CN112312904A (zh) 2018-04-16 2021-02-02 C4医药公司 螺环化合物
EP3578561A1 (en) 2018-06-04 2019-12-11 F. Hoffmann-La Roche AG Spiro compounds
CN112601751B (zh) * 2018-06-13 2024-04-02 拜欧斯瑞克斯公司 稠合噻吩化合物
AR116109A1 (es) 2018-07-10 2021-03-31 Novartis Ag Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
US11192877B2 (en) 2018-07-10 2021-12-07 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
AU2019309894A1 (en) 2018-07-27 2021-01-28 Biotheryx, Inc. Bifunctional compounds as CDK modulators
CN113423701A (zh) * 2018-11-13 2021-09-21 拜欧斯瑞克斯公司 取代的异吲哚啉酮
US11548870B2 (en) 2019-11-19 2023-01-10 Bristol-Myers Squibb Company Compounds useful as inhibitors of helios protein
US11897930B2 (en) 2020-04-28 2024-02-13 Anwita Biosciences, Inc. Interleukin-2 polypeptides and fusion proteins thereof, and their pharmaceutical compositions and therapeutic applications
WO2022066835A1 (en) * 2020-09-23 2022-03-31 St. Jude Children's Research Hospital, Inc. Substituted n-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-5-yl)arylsulfonamide analogs as modulators of cereblon protein
BR112023020077A2 (pt) 2021-04-06 2023-11-14 Bristol Myers Squibb Co Compostos de oxoisoindolina substituída por piridinila

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552397A (en) * 1992-05-18 1996-09-03 E. R. Squibb & Sons, Inc. Substituted azepinone dual inhibitors of angiotensin converting enzyme and neutral exdopeptidase
WO1997038705A1 (en) * 1996-04-12 1997-10-23 Bristol-Myers Squibb Company N-formyl hydroxylamine containing compounds useful as ace inhibitors and/or nep inhibitors
ATE530542T1 (de) 1996-07-24 2011-11-15 Celgene Corp Amino substituierte 2-(2,6-dioxopiperidin-3-yl)- phthalimide zur verringerung der tnf-alpha-stufen
BR9908811A (pt) 1998-03-16 2000-12-05 Celgene Corp Composto, composição farmacêutica e seu uso no tratamento de mamìferos
US7968708B2 (en) 2006-12-06 2011-06-28 The Research Foundation Of State University Of New York Azepans and methods for making and using same
AU2013355054B2 (en) * 2012-12-07 2017-08-24 Chemocentryx, Inc. Diazole lactams
CN104004122B (zh) * 2014-05-08 2016-05-11 中国科学院长春应用化学研究所 新型温敏性聚合物及用可再生资源l-赖氨酸制备新型温敏性聚合物的方法
MX2017014567A (es) 2015-05-22 2018-06-28 Biotheryx Inc Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos.
CN109562107A (zh) 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
WO2017201069A1 (en) 2016-05-18 2017-11-23 Biotheryx, Inc. Oxoindoline derivatives as protein function modulators

Also Published As

Publication number Publication date
JP2019194253A (ja) 2019-11-07
SG11201708303XA (en) 2017-11-29
CA2986141A1 (en) 2016-12-01
RU2694895C2 (ru) 2019-07-18
WO2016191178A1 (en) 2016-12-01
US20160362397A1 (en) 2016-12-15
KR20180005174A (ko) 2018-01-15
JP6629885B2 (ja) 2020-01-15
ZA201707749B (en) 2020-05-27
TW201710252A (zh) 2017-03-16
HK1253065A1 (zh) 2019-06-06
AU2016266942A1 (en) 2017-12-07
CA2986141C (en) 2020-07-28
US10669260B2 (en) 2020-06-02
IL255589A (en) 2018-01-31
JP2018515545A (ja) 2018-06-14
RU2017139768A (ru) 2019-06-24
NZ737355A (en) 2019-05-31
KR102055491B1 (ko) 2019-12-12
CN107787320B (zh) 2020-12-04
AU2016266942B2 (en) 2018-10-18
EP3298004A1 (en) 2018-03-28
EP3298004B1 (en) 2021-01-06
CN107787320A (zh) 2018-03-09
US9822098B2 (en) 2017-11-21
RU2017139768A3 (es) 2019-06-24
TWI650320B (zh) 2019-02-11
US20180065952A1 (en) 2018-03-08
IL255589B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
MX2017014567A (es) Compuestos que tienen como dianas a proteinas, composiciones, metodos y usos de los mismos.
MX2019007434A (es) Derivados de tienopirrol para uso en seleccion como diana de proteinas, composiciones, metodos y usos de los mismos.
MX2021006615A (es) Proteinas de union triespecificas y metodos de uso.
CL2018003153A1 (es) Moléculas de anticuerpo para el tratamiento del cáncer.
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
WO2017024317A3 (en) Methods to induce targeted protein degradation through bifunctional molecules
MX2019006045A (es) Proteinas triespecificas dirigidas a psma y metodos de uso.
MX2018010824A (es) Proteinas de union inducibles y metodos de uso.
MX2018013784A (es) Proteinas de fusion gdf15 y usos de estas.
ZA201908214B (en) Anti-bcma heavy chain-only antibodies
EA201791137A1 (ru) Новые замещенные индазолы, способы их получения, содержащие их фармацевтические препараты и их применение для получения лекарственных средств
HRP20220531T1 (hr) Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda
WO2017011820A3 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
BR112016018288A2 (pt) proteínas de fusão de interleucina 2 e uso das mesmas
EA201790463A1 (ru) Создание гаплоидных растений
WO2016054598A3 (en) Antibodies that bind ebola glycoprotein and uses thereof
EA201791422A1 (ru) Фармацевтические продукты и устойчивые жидкие композиции антител к il-17
MX2019015563A (es) Anticuerpos anti-bcma unicamente de cadena pesada.
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
PH12019500571A1 (en) Anti-pd-1 antibodies
DK3233129T3 (da) Nukleinsyrekonstrukter og genterapivektorer til anvendelse i behandlingen af wilsons sygdom og andre lidelser
MX2022006575A (es) Uso de anticuerpos anti-il-23a para tratar enfermedades inflamatorias.
MX2016012479A (es) Miembros de unión al factor de necrosis tumoral (tnf) alfa.
EA201790505A1 (ru) Соединение, нацеленое на ил-23а и фно-альфа, и его применение
WO2016200614A3 (en) Bacteria engineered to treat diseases associated with hyperammonemia